Abstract
Background Non-invasive estimation of mean pulmonary artery pressure (mPAP) by cardiovascular magnetic resonance (CMR) four-dimensional (4D) flow analysis has shown excellent agreement with invasive right heart catheterization. However, clinical application is limited by relatively long scan times.
Objectives The aim of this study was to evaluate the accuracy and time reduction of compressed sensing (CS) accelerated acquisition for mPAP estimation.
Methods Patients (n=51) referred for clinical CMR at 1.5T or 3T underwent imaging with both a prototype CS□accelerated and a non-CS-accelerated flow sequence acquiring time-resolved multiple 2D slice phase contrast three-directional velocity-encoded images covering the pulmonary artery. Prototype software was used for blinded analysis of pulmonary artery (PA) vortex duration to estimate mPAP as previously validated.
Results CS-accelerated and non-CS-accelerated acquisition showed increased mPAP in 22/51 (43%) and 24/51 (47%) patients, respectively. Mean bias for estimating mPAP between the two methods was 0.1±1.9 mmHg and the intraclass correlation coefficient was 0.97 [95% confidence interval 0.94-0.98]. Effective scan time was lower for the CS-accelerated acquisition (1 min 55 sec ± 27 sec vs 9 min 6 sec ± 2 min 20 sec, p<0.001, 79% reduction).
Conclusions CS-accelerated CMR acquisition enables preserved accuracy for estimating mPAP compared to a non-CS-accelerated sequence, allowing for an average scan time of less than 2 minutes. CS-acceleration thereby increases the clinical utility of CMR 4D flow analysis to estimate mPAP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was funded in part by the Swedish Research Council, Swedish Heart and Lung Foundation, the Stockholm County Council and Karolinska Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Stockholm Regional Board of ethics committee (EPN: 2011/1077-31/3).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Grant support The research was funded in part by the Swedish Research Council, Swedish Heart and Lung Foundation, the Stockholm County Council and Karolinska Institute.
Data Availability
All data produced in the present work are contained in the manuscript
Abbrevations and Acronyms
- PH
- Pulmonary hypertension
- mPAP
- Mean pulmonary artery pressure
- HF
- Heart failure
- RHC
- Right heart catheterization
- LV
- Left ventricle
- RV
- Right ventricle
- CS
- Compressed sensing